Therapeutic strategies in multidrug-resistant pulmonary tuberculosis: impact of bedaquiline as a pharmacological innovation
DOI:
https://doi.org/10.56294/evk2025240Keywords:
MDR-TB, bedaquiline, therapeutic efficacy, adverse effects and clinical improvementAbstract
MDR-TB is a considerable challenge for global public health given the growing resistance to conventional drugs. This article evaluates the efficacy and safety of bedaquiline, an inhibitor of Mycobacterium tuberculosis ATP synthase, in the pharmacotherapy of multidrug-resistant pulmonary tuberculosis. Using the PRISMA method, 20 investigations from international data were selected with the objective of evaluating therapeutic efficacy, adverse effects and clinical improvement in patients undergoing treatments with regimens that incorporate bedaquiline. The findings indicate that these interventions achieve success rates exceeding 80%, with accelerated bacteriological conversion during the first weeks of treatment. Although adverse effects such as QTc interval prolongation, hepatotoxicity, peripheral neuropathy, myelosuppression, and hematologic toxicity were documented, these were manageable with appropriate follow-up. The article concludes that bedaquiline constitutes an essential progress in the treatment of MDR-TB, although its high cost and monitoring restrict its accessibility.
References
1. Tuberculosis [Internet]. [citado el 21 de diciembre de 2024]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/tuberculosis
2. Tuberculosis multirresistente [Internet]. [citado el 21 de diciembre de 2024]. Disponible en: https://www.who.int/es/news-room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb)
3. Palmero DJ, Lagrutta L, Inwentarz SJ, Vescovo M, Aidar OJ, Montaner PJG. TRATAMIENTO DE LA TUBERCULOSIS DROGORRESISTENTE EN ADULTOS Y NIÑOS. REVISIÓN NARRATIVA. 2022;
4. Distribución geográfica y factores de riesgo de tuberculosis multidrogorresistente en el centro de Perú [Internet]. [citado el 21 de diciembre de 2024]. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-00112020000200245
5. Edith N, Marin M, Eugenia M. Bedaquilina en el tratamiento de tuberculosis multirresistente en pediatría. 2024;24.
6. Palmero DD. Tuberculosis 2024: ¿hemos avanzado? 2024;
7. Sun WW, Yang M, Chen XH, Fan LC, Wu HY, Zhang SJ, et al. Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study. Expert Rev Anti Infect Ther. abril de 2024;22(4):219–27.
8. Deshkar AT, Shirure PA. Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis. Cureus. agosto de 2022;14(8):e28519.
9. Ahmad A, Akhtar J, Ahmad M, Khan MI, Wasim R, Islam A, et al. Bedaquiline: An Insight Into its Clinical Use in Multidrug-Resistant Pulmonary Tuberculosis. Drug Res. julio de 2024;74(6):269–79.
10. Mikiashvili L, Kempker RR, Chakhaia TS, Bablishvili N, Avaliani Z, Lomtadze N, et al. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis. Clin Infect Dis Off Publ Infect Dis Soc Am. el 10 de abril de 2024;78(4):1043–52.
11. Desai G, Purohit G, Borana H, Deokar K, Yogi S. Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study. Monaldi Arch Chest Dis Arch Monaldi Mal Torace. el 4 de mayo de 2022;93(1).
12. Geng X, Yang Y, Wen XT, Long HF, Li YX, Liu YX, et al. [Comprehensive clinical evaluation of bedaquiline in the treatment of multidrug-resistant tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi Chin J Tuberc Respir Dis. el 12 de junio de 2023;46(6):572–9.
13. Oelofse S, Esmail A, Diacon AH, Conradie F, Olayanju O, Ngubane N, et al. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. el 1 de junio de 2021;25(6):453–60.
14. Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. abril de 2021;27(4):597–602.
15. Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, et al. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study. Lancet Infect Dis. 2024;24(10):1151–61.
16. Tong E, Wu Q, Chen Y, Liu Z, Zhang M, Zhu Y, et al. The Efficacy and Safety of Bedaquiline in the Treatment of Pulmonary Tuberculosis Patients: A Systematic Review and Meta-Analysis. Antibiotics. 2023;12(9).
17. Ke H, Gui X, Sun W, Zhang S, Yang Y, Zhang Z, et al. The Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China. Infect Drug Resist. 2023;16:5055–64.
18. Yu CH, Liu X, Shen LJ, Li HW, Li X, Wu RS, et al. Meta analysis of efficacy and safety of the treatment containing bedaquiline for multidrug-resistant pulmonary tuberculosis. Chin J Antituberc. 2022;44(7):660–8.
19. Sakhelashvili MI, Platonova IL, Sakhelashvili-Bil OI, Piskur ZI. Evaluation of the effectiveness of bedaquiline and delamanid treatment among children and adolescents with multi-drug-resistant pulmonary tuberculosis. Mod Pediatr Ukr. 2023;(2(130)):17–23.
20. Scopus - Document details - Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China | Signed in [Internet]. [citado el 30 de diciembre de 2024]. Disponible en: https://www.scopus.com/record/display.uri?eid=2-s2.0-85204358209&origin=resultslist&sort=plf-f&src=s&sot=b&sdt=cl&cluster=scosubtype%2C%22ar%22%2Ct&s=TITLE-ABS-KEY%28tuberculosis+AND+pulmonary+AND+multidrug-resistant+bedaquiline+AND+treatment+AND+efficacy%29&sessionSearchId=07589dbb8f5b8874adde7649473caf13&relpos=2
21. Scopus - Document details - A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis | Signed in [Internet]. [citado el 30 de diciembre de 2024]. Disponible en: https://www.scopus.com/record/display.uri?eid=2-s2.0-85206993517&origin=resultslist&sort=plf-f&src=s&sot=b&sdt=cl&cluster=scosubtype%2C%22ar%22%2Ct&s=TITLE-ABS-KEY%28tuberculosis+AND+pulmonary+AND+multidrug-resistant+bedaquiline+AND+treatment+AND+efficacy%29&sessionSearchId=07589dbb8f5b8874adde7649473caf13&relpos=1
22. Scopus - Document details - Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial | Signed in [Internet]. [citado el 30 de diciembre de 2024]. Disponible en: https://www.scopus.com/record/display.uri?eid=2-s2.0-85194578486&origin=resultslist&sort=plf-f&src=s&sot=b&sdt=cl&cluster=scosubtype%2C%22ar%22%2Ct&s=TITLE-ABS-KEY%28tuberculosis+AND+pulmonary+AND+multidrug-resistant+bedaquiline+AND+treatment+AND+efficacy%29&sessionSearchId=07589dbb8f5b8874adde7649473caf13&relpos=7
23. Scopus - Document details - Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis | Signed in [Internet]. [citado el 30 de diciembre de 2024]. Disponible en: https://www.scopus.com/record/display.uri?eid=2-s2.0-85151838124&origin=resultslist&sort=plf-f&src=s&sot=b&sdt=cl&cluster=scosubtype%2C%22ar%22%2Ct&s=TITLE-ABS-KEY%28tuberculosis+AND+pulmonary+AND+multidrug-resistant+bedaquiline+AND+treatment+AND+efficacy%29&sessionSearchId=07589dbb8f5b8874adde7649473caf13&relpos=18
24. Scopus - Document details - Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan | Signed in [Internet]. [citado el 30 de diciembre de 2024]. Disponible en: https://www.scopus.com/record/display.uri?eid=2-s2.0-85206595553&origin=resultslist&sort=plf-f&src=s&sot=b&sdt=cl&cluster=scosubtype%2C%22ar%22%2Ct&s=TITLE-ABS-KEY%28tuberculosis+AND+pulmonary+AND+multidrug-resistant+bedaquiline+AND+treatment+AND+efficacy%29&sessionSearchId=07589dbb8f5b8874adde7649473caf13&relpos=4
25. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. el 5 de marzo de 2020;382(10):893–902.
26. Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet Lond Engl. el 26 de noviembre de 2022;400(10366):1858–68.
27. Goodall RL, Nunn AJ, Meredith SK, Bayissa A, Bhatnagar AK, Chiang CY, et al. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. diciembre de 2024;12(12):975–87.
28. Fu L, Weng T, Sun F, Zhang P, Li H, Li Y, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. octubre de 2021;111:138–47.
29. Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. febrero de 2024;12(2):117–28.
30. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. el 1 de septiembre de 2022;387(9):810–23.
31. Kim JH, Kwon OJ, Kim YS, Park MS, Hwang S, Shim TS. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation. Respir Investig. enero de 2020;58(1):45–51.
32. Dawson R, Diacon AH, Takuva S, Liu Y, Zheng B, Karwe V, et al. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy. TRIALS. el 19 de enero de 2024;25(1):70.
33. Afifi M, Amin W, Helal D, Ashmawy R, El-Maradny YA, Khalifa N, et al. Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt. Sci Rep. el 1 de julio de 2024;14(1):16247.
34. Fadeyi MO, Decroo T, Ortuño-Gutiérrez N, Ahmed B, Jinadu A, El-Tayeb O, et al. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria. Int Health. el 1 de enero de 2024;16(1):123–5.
35. Moodliar R, Aksenova V, Frias MVG, van de Logt J, Rossenu S, Birmingham E, et al. Bedaquiline for multidrug-resistant TB in paediatric patients. Int J Tuberc Lung Dis. el 1 de septiembre de 2021;25(9):716–24.
36. Yao G, Zhu M, Nie Q, Chen N, Tu S, Zhou Y, et al. Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis. J Int Med Res. el 1 de enero de 2023;51(1):3000605221148416.
37. Padmapriyadarsini C, Oswal VS, Jain CD, Mariappan MV, Singla N, Kumar S, et al. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clin Infect Dis Off Publ Infect Dis Soc Am. el 17 de diciembre de 2024;79(6):1375–85.
38. Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, et al. Treatment Strategy for Rifampin-Susceptible Tuberculosis. N Engl J Med. 2023;388(10):873–87.
39. Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331–43.
40. Scopus - Document details - Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety [Internet]. [citado el 14 de enero de 2025]. Disponible en: https://www.scopus.com/record/display.uri?eid=2-s2.0-85102843752&origin=resultslist&sort=plf-f&src=s&sot=b&sdt=cl&s=TITLE-ABS-KEY%28tuberculosis+AND+pulmonary+AND+multidrug-resistant+AND+bedaquiline+AND+treatment+AND+efficacy%29&sessionSearchId=58c4af2909bcf380f5d1b43b6511b45a&relpos=40.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 D. Castro Guerra , Enzo Bazualdo Fiorini , Segundo Bueno Ordoñez (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
